Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kaleido Biosciences (KLDO) stocks in Canada

Learn how to easily invest in Kaleido Biosciences stocks.

Kaleido Biosciences is a biotechnology business based in the US. Kaleido Biosciences stocks (KLDO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.57 – a decrease of 12.5% over the previous week. Kaleido Biosciences employs 82 staff and has a trailing 12-month revenue of around $855,000.

How to buy shares in Kaleido Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KLDO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kaleido Biosciences stock price (NASDAQ:KLDO)

Use our graph to track the performance of KLDO stocks over time.

Kaleido Biosciences shares at a glance

Information last updated 2022-01-25.
Latest market close$1.89
52-week range$1.90 - $20.50
50-day moving average $3.14
200-day moving average $5.45
Wall St. target price$14.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.24

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Kaleido Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Kaleido Biosciences price performance over time

Historical closes compared with the close of $1.89 from 2022-01-27

1 week (2022-01-21) -12.50%
1 month (2021-12-29) -25.30%
3 months (2021-10-29) -56.05%
6 months (2021-07-29) -66.78%
1 year (2021-01-29) -87.36%
2 years (2020-01-29) -79.70%
3 years (2019-01-25) N/A
5 years (2017-01-25) N/A

Kaleido Biosciences financials

Revenue TTM $855,000
Gross profit TTM $-54,992,000
Return on assets TTM -77.39%
Return on equity TTM -276.59%
Profit margin 0%
Book value $0.69
Market capitalisation $96.3 million

TTM: trailing 12 months

Kaleido Biosciences share dividends

We're not expecting Kaleido Biosciences to pay a dividend over the next 12 months.

Kaleido Biosciences share price volatility

Over the last 12 months, Kaleido Biosciences's shares have ranged in value from as little as $1.9001 up to $20.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kaleido Biosciences's is -0.3864. This would suggest that Kaleido Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Kaleido Biosciences has bucked the trend.

Kaleido Biosciences overview

Kaleido Biosciences, Inc. , a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. It also has a strategic collaboration with the COPD Foundation to study KB109 in patients with chronic obstructive pulmonary disease. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site